A potential new treatment for cancer is now one step closer to being on the market. This will bring hope to the 14 millions people who are currently battling this incurable disease.
Australian biotech company. Propanc Health Group(OTCQB : PPCH), a company that has been creating proprietary treatments for patients with cancer from solid tumors like pancreatic, colorectal, and ovarian cancers, just completed a toxicokinetic study of 28 days to confirm a safe starting dose for patients. It is now moving towards clinical trials for PRP, its lead product.
The study data will form the basis for a clinical trial request in the United Kingdom. It also defines conditions for a planned four week regulatory Good Laboratory Practice compliant toxicology research. Results are expected in early 2017.
This type of research is an important part in the development of new therapeutic drugs before clinical testing in humans.
“We are making excellent progress completing these studies for PRP,”Propanc’s chief executive Officer James Nathanielsz “Preclinical efficacy is well-established and the safety studies are pivotal because they provide the rationale for a safe starting dose for patient trials.”
Propanc’s Proenzyme Product, PRP, could be a game changer in cancer care. It offers an effective alternative for long-term treatment without the high toxicity of many current treatments.
“My scientific colleagues and I believe a cancer stem cell targeting therapy, which reduces chemo-resistance and supports immune function could become a significant addition to the treatment process,”Propanc’s Chief Scientific Officer, Dr. Julian Kenyon. “PRP is going to be a part of many different cancer combinatorial regimes, which is why we’re keen to follow up on the immuno-biological aspects of PRP in future trials.”
Visit PPCH.com for more information. www.propanc.com.
